Drugs / Hib 2.5
last change Aug 2010 re-read 2 minutes ago

Hib 2.5

Vaccine

Developed for
haemophilus infectious disease
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01061541 Aug 2003 → Jan 2004 haemophilus infectious disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Hib 2.5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01061541
Modality Vaccine “investigational DTPw-HBVLT/Hib2.5 vaccinePMID 20657177 Aug 2010
Route Intramuscular “One dose as intramuscular injection at 6, 10 and 14 weeks of age.” NCT01061541